23 Business Park Drive
40 articles with Isoplexis
IsoPlexis acquires extensive DNA and RNA sequencing portfolio to enable integrated single-cell sequencing and proteomic solutions
The integration of the sequence of each single cell coupled with IsoPlexis' proprietary functional proteomics accelerates insights into discovery biology & development of advanced medicines
IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe.
IsoPlexis Strengthens Commercial Leadership with the Appointment of Jason Ou as Asia-Pacific General Manager
IsoPlexis, the leader in single-cell proteomics, announced that Jason Ou has joined the company as General Manager for the Asia-Pacific region.
IsoPlexis announced that it has been named by Fierce Medtech as one of 2020's Fierce 15, designating it as one of the most promising private companies in the industry.
IsoPlexis announced that its IsoSpark system has been named a winner in the 2021 BIG Innovation Awards presented by the Business Intelligence Group.
Funding to accelerate global expansion of installed base and deliver new solutions at the convergence of single-cell biology and proteomics
IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay, will present at Citi's Spotlight on Diagnostics on Thursday, December 17th
IsoPlexis' Single-Cell Intracellular Proteome solution has been recognized for its impact on the development of better targeted and edited therapies and its potential to innovate and accelerate medical research
IsoPlexis, the leader in single-cell functional proteomics, announced today that Chief Executive Officer and Co-Founder, Sean Mackay , will present at Evercore ISI's 3 rd Annual HealthCONx Conference on Wednesday, December 2 nd at 9:40 a.m. ET .
IsoPlexis' Blood-Based Biomarker Predicts Response and Progression-Free Survival to a Novel IL-2 Agonist and Checkpoint Inhibitor Doublet Therapy in a Phase 2 Study of Metastatic Melanoma Patients
IsoPlexis' single-cell proteomics was shown to be a non-invasive and predictive biomarker of response data presented at SITC 2020 Annual Meeting for the PIVOT-02 Trial
IsoPlexis Launches Personalized Lab System, the IsoSpark, to Continue Scaling to Many Labs Worldwide
The new IsoSpark instrument makes IsoPlexis' unique functional proteomics accessible to every lab, providing an integrated and flexible solution for accelerating curative medicines.
Yale University to use IsoPlexis' single-cell immune landscaping & high-plex automated immunoassay solutions to conduct blood-based immune profiling in COVID-19 and identify rapid circulating markers [08-October-2020] BRANFORD, Conn. , Oct. 8, 2020 /PRNewswire/ -- IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with Yale
IsoPlexis, the leader in single-cell proteomics, today announced their Single-Cell Proteomics COVID-19 Grant Challenge, where researchers are invited to share next generation insights using single-cell functional proteomics for the opportunity to win 12 IsoCode or CodePlex chips for a project run on the IsoLight system.
IsoPlexis partners with Medquest to expand its single-cell proteomic analysis platform, the IsoLight system and IsoCode & CodePlex Chips, throughout the pharmaceutical and life science markets in Malaysia and Singapore [25-August-2020] BRANFORD, Conn. , Aug. 25, 2020 /PRNewswire/ -- IsoPlexis, the leader in single-cell proteomics products, today announced an exclu
IsoPlexis and Lonza Collaborate to Enable the Next Generation of Precision Cell Therapy Manufacturing
- Lonza to utilize of IsoPlexis' IsoLight® automated proteomics platform - IsoLight® to be used for functional quality analytics for cell therapy products produced on Lonza's Cocoon® Platform, an automated cell manufacturing platform [20-August-2020] BASEL, Switzerland and BRANFORD, Conn. , Aug. 20, 2020 /PRNewswire/ -- Quote from Matthew Hewitt , Hea
IsoPlexis, the leader in single-cell functional proteomics, today announced a partnership with the Division of Infectious Diseases, Department of Medicine at Columbia University, IsoPlexis' Single-Cell Secretome immune profiling solutions will be used to study cellular drivers of durable and protective immune response to COVID-19.
IsoPlexis Announces Partnership with Neoline Technology Co & IsoLight Expansion into Chinese Life Science Market
IsoPlexis partners with Neoline to extend sales of its single-cell proteomic analysis platform, IsoLight and IsoCode & CodePlex Chips, to the pharmaceutical and life science markets in China
IsoPlexis Strengthens Commercial Leadership with the Appointment of Peter Siesel as Chief Commercial Officer
IsoPlexis, the leader in single-cell proteomics, today announced that Peter Siesel has joined the company as Chief Commercial Officer. In this role, Mr. Siesel will continue to advance IsoPlexis' commercialization and market expansion efforts by leading global sales and customer support, as well as expansion into key regions for ma
IsoPlexis Awarded $2 Million NIH Phase 2 SBIR Grant for Expanding Development of a Cellular Platform for Analyzing the Peripheral Immune Response in Alzheimer's Disease and Neuroinflammation with Single-cell Proteomics
IsoPlexis secures grant funding to expand Alzheimer's applications using functional single-cell proteomics on the IsoLight system
IsoPlexis Strengthens Executive Leadership Team with Appointment of John Strahley as Chief Financial Officer
IsoPlexis, the leader in functional cellular proteomics, today announced the appointment of John Strahley as Chief Financial Officer.